Study
Breast Cancer - Subtype defined by an amplification of the HER2 gene
Study ID | Alternative Stable ID | Type |
---|---|---|
EGAS00001001431 | Other |
Study Description
Clinically positive HER2 (cHER2+) breast cancers (BC) are defined by the amplification and overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12 and represent 15% of all BCs. Although anti-HER2 targeted therapies have improved BC’s natural history, the magnitude of their benefit varies widely between patients and deciphering the genomic heterogeneity of cHER2+ BC may provide a basis to better understand patients’ outcome. As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 cHER2+ primary invasive carcinomas.
Study Datasets 6 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001001844 |
Whole genome sequencing of 64 HER2-Positive Breast Cancer
|
Illumina HiSeq 2000 | 128 |
EGAD00001003189 |
Whole genome sequencing of 8 HER2-Positive Breast Cancer (in complement to EGAD00001001844)
|
Illumina HiSeq 2000 | 16 |
EGAD00010000886 |
samples using Affymetrix HG_U133_+2
|
Affymetrix HG_U133_+2 | 99 |
EGAD00010000919 |
samples using Illumina HUMANOMNI1QUAD
|
HUMANOMNI1QUAD | 2 |
EGAD00010000920 |
samples using Illumina HUMANOMNIEXPRESS
|
HUMANOMNIEXPRESS | 50 |
EGAD00010000921 |
samples using Affymetrix CYTOSCANHD
|
CYTOSCANHD | 12 |
Who archives the data?

Publications
Citations
Retrieving...

Retrieving...
